- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT01195311
A Dose-escalation Study in Subjects With Advanced Malignancies
A Phase I, Open-Label, Dose-Escalation Study to Determine the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of INCB024360 in Patients With Advanced Malignancies
This is an open label, dose escalation study using a 3 + 3 design to determine if INCB024360 (study drug) is safe, well-tolerated and effective in patients with advanced malignancies. Patients will be enrolled and treated in cohorts of three and each observed a minimum of 28 days before the next group is enrolled and may begin to receive study drug. For subject safety, the first subject in each cohort will be administered drug for one week before the next two subjects in the cohort can begin drug administration. Doses will be escalated unless a dose-limiting toxicity (DLT) is observed in one of three subjects.
An expanded cohort of up to 15 patients may be recruited to further explore safety at the 'maximum tolerated dose' or at a lower, pharmacologically active, dose.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
Illinois
-
Chicago, Illinois, Forenede Stater
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Subjects with neoplastic disease refractory to currently available therapies or for which no effective treatment is available
- Subjects with life expectancy of 12 weeks or longer.
- Subjects with Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
Exclusion Criteria:
- Subjects who received any anti-cancer medications in the 21 days prior to receiving their first dose of study medication or 6 weeks for mitomycin-C or nitrosoureas.
- Subjects with history of brain metastases or spinal cord compression.
- Subjects who have undergone a bone marrow or solid organ transplant.
- Subjects who have had major surgery within 4 weeks prior to study entry or had minor surgical procedure within 7 days prior to initiating treatment.
- Subjects with a history of any gastrointestinal condition
- Is receiving any compound that is known to be a potent inducer or inhibitor of CYP3A4
- Subjects with an active autoimmune process or is receiving therapy for an autoimmune disease
- Subjects treated with a serotonin reuptake inhibitor within 3 weeks prior to study entry
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: N/A
- Interventionel model: Enkelt gruppeopgave
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
---|---|
Eksperimentel: INCB024360
|
INCB024360: 25 mg and 100 mg tablets Doses will be escalated in accordance with the dosing schedule.
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
---|---|
Safety and tolerability as measured by adverse events and dose limiting toxicities
Tidsramme: Measured from baseline through follow-up period (measured during cycle 1 weekly and bi monthly thereafter)
|
Measured from baseline through follow-up period (measured during cycle 1 weekly and bi monthly thereafter)
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
---|---|
Tumor assessment as measured by RECIST criteria
Tidsramme: Measured from baseline through treatment cessation. (Measured every other cycle and end of study)
|
Measured from baseline through treatment cessation. (Measured every other cycle and end of study)
|
Measurement of IDO inhibition in whole blood measured through blood sampling.
Tidsramme: Cycle 1, Day 1 and each 28 day subsequent cycle at Day 1
|
Cycle 1, Day 1 and each 28 day subsequent cycle at Day 1
|
PK analysis
Tidsramme: Full PK at Days 1, 8 (trough only), 15 at Cycle 1 and trough at each subsequent cycle at Day 1
|
Full PK at Days 1, 8 (trough only), 15 at Cycle 1 and trough at each subsequent cycle at Day 1
|
Samarbejdspartnere og efterforskere
Sponsor
Datoer for undersøgelser
Studer store datoer
Studiestart
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Skøn)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- INCB 24360-101
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .
Kliniske forsøg med Solide tumorer og hæmatologisk malignitet
-
Memorial Sloan Kettering Cancer CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRekrutteringSolid tumor | Solid tumor, voksen | Solid tumor, uspecificeret, voksenForenede Stater, Puerto Rico
-
Sorrento Therapeutics, Inc.Trukket tilbageSolid tumor | Recidiverende solid tumor | Refraktær tumor
-
BeiGeneRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, New Zealand, Australien, Kina
-
Anjali PawarRekrutteringSolid tumor | Solid tumor, barndomForenede Stater
-
Impact Therapeutics, Inc.RekrutteringSolid tumor | Avanceret solid tumorKina, Taiwan, Forenede Stater, Australien
-
Partner Therapeutics, Inc.Trukket tilbageSolid tumor | Solid tumor, voksenForenede Stater
-
Novartis PharmaceuticalsAfsluttetKræft | Solid tumor | Avanceret solid tumorJapan
-
Pyxis Oncology, IncRekrutteringSolid tumor | Avanceret solid tumorForenede Stater, Spanien, Belgien
Kliniske forsøg med INCB024360
-
Incyte CorporationAfsluttetIkke-operable eller metastatiske faste tumorerForenede Stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)Trukket tilbageStadie IV Ovarieepitelkræft | Tilbagevendende ovarieepitelkræft | Tilbagevendende primær peritonealhulekræft | Fase IV Primær peritonealhulekræft | Tilbagevendende æggelederkræft | Stadie IIA Æggelederkræft | Stadie IIB Æggelederkræft | Stadie IIC Æggelederkræft | Stadie IIIA Æggelederkræft | Stadie IIIB Æggelederkræft og andre forhold
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeFase III æggelederkræft AJCC v7 | Fase III Kræft i æggestokkene AJCC v6 og v7 | Fase III Primær Peritoneal Cancer AJCC v7 | Fase IIIA Æggelederkræft AJCC v7 | Fase IIIA Ovariekræft AJCC v6 og v7 | Fase IIIA Primær peritoneal cancer AJCC v7 | Fase IIIB Æggelederkræft AJCC v7 | Stadie IIIB Ovariekræft... og andre forholdForenede Stater
-
Incyte CorporationAstraZenecaAfsluttetHoved- og halskræft | Lungekræft | Faste tumorer | UC (urothelial cancer)Forenede Stater
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI); Incyte Corporation; University of VirginiaAfsluttetStadie IV Hudmelanom | Tilbagevendende melanom | Stadie IIIB Hudmelanom | Stadie IIIC Hudmelanom | Slimhinde melanom | Stadie IV Uveal melanom | Stadie IIIA Hudmelanom | Stadium IIIA Uveal melanom | Stadie IIIB Uveal melanom | Stadie IIIC Uveal melanom | Tilbagevendende uveal melanomForenede Stater
-
Incyte CorporationHoffmann-La Roche; Genentech, Inc.AfsluttetUC (urothelial cancer) | NSCLC (ikke-småcellet lungekarcinom)Forenede Stater
-
Incyte CorporationMerck Sharp & Dohme LLCAfsluttetMelanom | Lymfom | Hoved- og halskræft | Mavekræft | Livmoderhalskræft | Hepatocellulært karcinom (HCC) | Lungekræft | Blærekræft | Endometriecancer | Faste tumorer | Nyrecellekarcinom (RCC) | Tredobbelt negativ brystkræft (TNBC) | UC (urothelial cancer) | Mikrosatellit-instabilitet (MSI) Høj kolorektal cancer (CRC)Forenede Stater
-
Incyte Biosciences International SàrlAfsluttetMetastatisk kræft | Avancerede maligniteterForenede Stater
-
Incyte CorporationMerck Sharp & Dohme LLCAfsluttetLungekræftSpanien, Irland, Canada, Danmark, Japan, Israel, Korea, Republikken, Malaysia, Forenede Stater, Kalkun, Italien, Ukraine, Schweiz, Den Russiske Føderation, Polen, Australien, Estland, Det Forenede Kongerige
-
Incyte CorporationMerck Sharp & Dohme LLCAfsluttetUC (urothelial cancer)Forenede Stater, Frankrig, Belgien, Israel, Spanien, Det Forenede Kongerige, Korea, Republikken, Taiwan, Australien, Holland, Japan, Tyskland, Ukraine, Canada, Irland, Italien, Polen, Den Russiske Føderation